Skip to Content
You are currently on the new version of our website. Access the old version .
CancersCancers
  • Article
  • Open Access

11 August 2025

14 Pages

An In Silico Feasibility Study of Dose-Escalated Hypofractionated Proton Therapy for Rectal Cancer

,
,
,
,
,
,
,
and
1
Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, 14186 Stockholm, Sweden
2
Department of Oncology-Pathology, Karolinska Institute, 17177 Stockholm, Sweden
3
Danish Centre for Particle Therapy, Aarhus University Hospital, 8200 Aarhus, Denmark
4
Department of Clinical Medicine, Aarhus University, 8200 Aarhus, Denmark

Simple Summary

The incidence of colorectal cancer is increasing in young adults. Treatment often includes extensive surgery with burdensome late side effects. Radiation therapy along with chemotherapy is often used in combination before surgery and, in some cases, renders surgery unnecessary. The purpose of this study is to investigate the possibility of delivering larger radiation doses to patients without elevating the dose to healthy organs and tissue in the vicinity of the rectum. We considered two modalities of radiation: protons and photons. Our results indicate that it should be safe to give these higher doses with both radiation modalities. With protons the dose given to healthy tissue can be approximately reduced by half, compared to photons. A clinical trial would be required to verify the efficacy of larger doses to the tumor.

Abstract

Background/Objectives: The current standard treatment for locally advanced rectal cancer (LARC) is neoadjuvant chemoradiotherapy, or total neoadjuvant therapy (TNT), followed by total mesorectal excision (TME). If the neoadjuvant treatment results in a clinical complete response (cCR), non-operative management of LARC might be possible. It is hypothesized that cCR rates will increase with increasing radiotherapy doses. By using proton therapy, doses to organs at risk (OAR) may be decreased. In preparation for a clinical trial on dose-escalated proton therapy for LARC, the purpose of this study is to establish the feasibility of proton therapy for dose-escalated hypofractionated radiotherapy of LARC. Methods: Ten patients, having previously received short course radiotherapy (SCRT) for LARC, were included in this planning study. Two photon plans and two proton plans were created for each patient: one with a standard 5 × 5 Gy fractionation and one dose-escalated up to 5 × 7 Gy. Proton plans were robustly optimized. For all plans the integral dose (ID) was computed, and for the proton plans relative biological effectiveness (RBE) distributions were calculated. Feasibility was assessed in terms of target coverage and OAR doses. Results: All treatment plans satisfied target coverage criteria. Three of the photon and two of the proton dose-escalated plans exceeded recommended OAR objectives. Proton IDs were on average lower by a factor of 1.97 compared to photon IDs. Mean doses to OAR were, in general, lower for protons. All proton RBE values in the escalated target volumes were between 1.09 and 1.16. Conclusions: The proposed dose escalation was found to be feasible. Protons can reduce the integral dose and mean doses to OARs compared to photons in both the dose-escalated and non-escalated cases. Differences in RBE between escalated and standard fractionation were small.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.